Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism

Ann Oncol. 2011 Apr;22(4):988-990. doi: 10.1093/annonc/mdr010. Epub 2011 Feb 14.

Authors

E Bellini¹, A Pia², M P Brizzi¹, M Tampellini³, M Torta¹, M Terzolo², L Dogliotti¹, A Berruti⁴

Affiliations

¹ Department of Clinical and Biological Sciences; Department of Medical Oncology and.
² Department of Clinical and Biological Sciences; Department of Internal Medicine, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.
³ Department of Medical Oncology and.
⁴ Department of Medical Oncology and. Electronic address: alfredo.berruti@gmail.com.

PMID: 21321087
DOI: 10.1093/annonc/mdr010

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Benzenesulfonates / adverse effects*
Benzenesulfonates / therapeutic use
Fibroblast Growth Factor-23
Fibroblast Growth Factors / metabolism*
Humans
Hypophosphatemia / chemically induced*
Hypophosphatemia / metabolism*
Kidney Neoplasms / drug therapy
Male
Middle Aged
Niacinamide / analogs & derivatives
Phenylurea Compounds
Pyridines / adverse effects*
Pyridines / therapeutic use
Sorafenib

Substances

Antineoplastic Agents
Benzenesulfonates
FGF23 protein, human
Phenylurea Compounds
Pyridines
Niacinamide
Fibroblast Growth Factors
Fibroblast Growth Factor-23
Sorafenib